We are live on
!
Find out more
CC
Callan Capital Portfolio holdings
AUM
$1.35B
Turnover
17.35%
1-Year Est. Return
8.35%
This Fund
S&P 500
This Quarter
Est. Return
-20.97%
1 Year Est. Return
+8.35%
3 Year Est. Return
+20.11%
5 Year Est. Return
+98.58%
10 Year Est. Return
+95.87%
AUM
$184M
AUM Growth
-$292M
(-61%)
Cap. Flow
-$238M
Cap. Flow
% of AUM
-129.38%
Top 10 Holdings %
Top 10 Hldgs %
72.16%
Holding
80
New
10
Increased
15
Reduced
25
Closed
17
Avg Time Held
1.4
years
Top 10 Avg Time Held
0.5
years
Top 20 Avg Time Held
1
year
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ImmunityBio
IBRX
|
+$79.3M |
| 2 |
Schwab US Aggregate Bond ETF
SCHZ
|
+$4.15M |
| 3 |
Schwab US Broad Market ETF
SCHB
|
+$3.16M |
| 4 |
Schwab International Equity ETF
SCHF
|
+$2.41M |
| 5 |
ResMed
RMD
|
+$1.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RCPT
RECEPTOS INC COM STK (DE)
RCPT
|
+$160M |
| 2 |
State Street SPDR S&P Dividend ETF
SDY
|
+$47M |
| 3 |
Vanguard FTSE Europe ETF
VGK
|
+$25.8M |
| 4 |
First Trust Global Tactical Commodity Strategy Fund
FTGC
|
+$18.7M |
| 5 |
Xtrackers MSCI EAFE Hedged Equity ETF
DBEF
|
+$18.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 71.2% |
| 2 | Healthcare | 26.49% |
| 3 | Real Estate | 1.23% |
| 4 | Materials | 0.28% |
| 5 | Financials | 0.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
DELISTED
BIOMED REALTY TRUST INC
BMR
| $1.29M | 0.7% |
64,584
| – | – |
2014 Q3
4 quarters
|
|
27
Vanguard Energy ETF
VDE
$11.2B
| $1.17M | 0.63% |
13,769
+10,839
| +370% | +$1.03M |
2014 Q4
3 quarters
|
|
28
Alexandria Real Estate Equities
ARE
$7.29B
| $976K | 0.53% |
11,529
+5,020
| +77% | +$451K |
2014 Q2
5 quarters
|
|
29
State Street SPDR S&P 500 ETF Trust
SPY
$815B
| $942K | 0.51% |
4,916
+3,132
| +176% | +$635K |
2014 Q3
4 quarters
|
|
30
Vanguard Morningstar Large-Cap ETF
VV
$54.8B
| $887K | 0.48% |
10,079
+7
| +0.1% | +$653 |
2014 Q1
6 quarters
|
|
31
iShares MSCI Japan ETF
EWJ
$23.2B
| $820K | 0.45% |
17,934
-155,522
| -90% | -$7.67M |
2013 Q2
9 quarters
|
|
32
Neurocrine Biosciences
NBIX
$13.9B
| $597K | 0.32% |
15,000
| – | – |
2013 Q4
7 quarters
|
|
33
Vanguard FTSE Emerging Markets ETF
VWO
$124B
| $564K | 0.31% |
17,055
-254,250
| -94% | -$9.23M |
2013 Q2
9 quarters
|
|
34
WisdomTree Japan Hedged Equity Fund
DXJ
$2.35B
| $563K | 0.31% |
34,710
-194,601
| -85% | -$3.51M |
2013 Q2
9 quarters
|
|
35
Vanguard FTSE All-World ex-US ETF
VEU
$67.4B
| $531K | 0.29% |
12,452
-102,503
| -89% | -$4.73M |
2013 Q2
9 quarters
|
|
|
KND
36
DELISTED
Kindred Healthcare
KND
| $521K | 0.28% |
33,078
+6,610
| +25% | +$134K |
2014 Q3
4 quarters
|
|
|
MON
37
DELISTED
Monsanto Co
MON
| $520K | 0.28% |
6,098
| – | – |
2014 Q2
5 quarters
|
|
|
MBFI
38
DELISTED
MB Financial Corp
MBFI
| $513K | 0.28% |
15,705
| – | – |
2014 Q2
5 quarters
|
|
39
iShares MSCI All Country Asia ex Japan ETF
AAXJ
$3.75B
| $512K | 0.28% |
9,697
-25,535
| -72% | -$1.44M |
2013 Q2
9 quarters
|
|
40
iShares MSCI KLD 400 Social ETF
DSI
$5.53B
| $466K | 0.25% |
13,138
| – | – |
2013 Q2
9 quarters
|
|
41
State Street Multi-Asset Real Return ETF
RLY
$1.43B
| $463K | 0.25% |
20,425
-33,538
| -62% | -$808K |
2013 Q4
7 quarters
|
|
|
42
Xtrackers MSCI EAFE Hedged Equity ETF
DBEF
$9.26B
| $452K | 0.25% |
17,329
-660,039
| -97% | -$18.5M |
2014 Q2
5 quarters
|
|
43
Global X MLP & Energy Infrastructure ETF
MLPX
$3.47B
| $441K | 0.24% |
10,834
-12,775
| -54% | -$615K |
2014 Q3
4 quarters
|
|
44
iShares CMBS ETF
CMBS
$437M
| $410K | 0.22% |
7,910
-22,509
| -74% | -$1.16M |
2013 Q3
8 quarters
|
|
|
ZVO
45
DELISTED
Zovio Inc. Common Stock
ZVO
| $378K | 0.21% |
49,650
-67,074
| -57% | -$573K |
2014 Q1
6 quarters
|
|
46
iShares MSCI Pacific ex Japan ETF
EPP
$2.21B
| $348K | 0.19% |
9,502
-129,911
| -93% | -$5.21M |
2013 Q2
9 quarters
|
|
47
Tesla
TSLA
$1.43T
| $335K | 0.18% |
20,250
+300
| +2% | +$5.1K |
2014 Q2
5 quarters
|
|
48
State Street SPDR Bloomberg Emerging Markets Local Bond ETF
EBND
$2.26B
| $332K | 0.18% |
13,503
-44,638
| -77% | -$1.14M |
2013 Q4
7 quarters
|
|
|
SQNM
49
DELISTED
SEQUENOM INC NEW
SQNM
| $309K | 0.17% |
176,477
-100,000
| -36% | -$245K |
2013 Q3
8 quarters
|
|
50
iShares MSCI Canada ETF
EWC
$7.28B
| $296K | 0.16% |
12,889
-154,077
| -92% | -$3.79M |
2013 Q2
9 quarters
|
|
Similar funds
PRO
MBA
SIA
AP
MW
SBIA
LC
TW
Callan Capital's Q3 2015 Portfolio in Review
As of Q3 2015, Callan Capital held 80 positions worth $184M, down 61% from $477M the previous quarter. Its ten largest holdings account for 72% of the portfolio.
Callan Capital withdrew a net $238M in Q3 2015, closing 17 positions and reducing 25 holdings. Its most notable exit was RECEPTOS INC COM STK (DE), an estimated $160M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 71% of assets, down from 97% a quarter earlier, followed by Healthcare and Real Estate.
Against the trend, Callan Capital opened a new position in ImmunityBio worth $41.6M.
- Callan Capital's largest Q3 2015 buy was ImmunityBio: 3,632,461 shares worth $41.6M.
- Callan Capital added most to Vanguard Energy ETF in Q3 2015, an estimated $1.03M increase.
- Callan Capital's biggest Q3 2015 reduction was Vanguard FTSE Europe ETF, cutting an estimated $25.8M.
- Callan Capital fully exited RECEPTOS INC COM STK (DE) in Q3 2015, selling an estimated $160M.
- Callan Capital's ten largest holdings make up 72% of its $184M portfolio in Q3 2015.
- Callan Capital opened 10 new positions and closed 17 in Q3 2015.
- Callan Capital's portfolio value fell 61% quarter-over-quarter to $184M.
Based on Callan Capital's 13F filing for Q3 2015, filed 10 Nov 2015.